Tags : License Agreement

Novartis Signs an Option and License Agreement with Molecular Partners

Shots: Molecular Partners to receive $65.8M as up front, including equity, and will receive $164.7M as an option payment for both MP0420 and MP0423 along with royalties on sales of therapies. Novartis to get an option to in-license global rights of MP0420 and MP0423 During the option period, Molecular Partners will conduct a P-I study […]Read More

Novo Nordisk Signs a License Agreement with Chugai for Antibody

Shots: Chugai will receive an upfront, development milestone and royalties if the compound is launch as an approved Ab drug. Additionally, Chugai will receive a fee for technology access Novo Nordisk to get the rights to use several Chugai Ab engineering technologies for their research activities and optional right for the development and marketing of […]Read More

Roche Signs a License Agreement with Dyno to Develop AVV

Shots: Dyno to receive upfront and is eligible to receive ~$1.8B milestones including development and commercial milestones along with royalties on any product emerges during the collaboration Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy while Roche and Spark will conduct preclinical, clinical, and commercialization […]Read More

Gilead Signs an Exclusive License Agreement with Jounce for Cancer

Shots: Jounce to receive $85M up front, $685B as clinical, regulatory, and commercial milestone payments, $35M equity investment at a premium in Jounce upon closing along with royalties on global sales of therapies including JTX-1811. The transaction is expected to be closed in H2’20 Jounce will lead the development of JTX-1811 through IND clearance, and […]Read More

BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics

Shots: Dragonfly to receive $475M as up front and is eligible to receive development, regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002 BMS will be responsible for the development & […]Read More

Solasia Signs a License Agreement with Isofol to Develop and

Shots: Isofol to receive $100M as up front, development, regulatory and commercial milestones, and clinical development cost and is eligible to receive royalties on sales of the therapy and retain its right to the therapy in ROW Solasia will lead clinical development activities in Japan and will be responsible for registrational filing and approval in […]Read More

AstraZeneca Signs a License Agreement with Redx Pharma for RXC006

Shots: Redx to receive $17M in early payment by the time of successful commencement of a P-I study, $360M as development, a regulatory and commercial milestone along with royalties on sales of the RXC006 AstraZeneca to get an exclusive global license to further develop & commercialize RXC006 targeting fibrotic diseases including IPF Redx continues to […]Read More

Zai Lab Signs an Exclusive License Agreement with Turning Point

Shots: Turning Point to receive $25M as upfront, $151M as development, regulatory and commercial milestones along with royalties on sales of repotrectinib in Greater China. Zai Lab to get exclusive rights to develop and commercialize repotrectinib in Greater China including China, Hong Kong, Macau, and Taiwan Zai Lab anticipates opening additional sites for the TRIDENT-1 […]Read More

Biogen Signs a License Agreement with Massachusetts Eye and Ear

Shots: Biogen will receive an exclusive license to develop the product worldwide and will be responsible for all US FDA required IND enabling studies, clinical development, and commercialization The companies collaborated to develop a therapy for IRDs due to mutations in the PRPF31 gene. Research performed at Harvard Ophthalmology demonstrated that AAV-mediated gene augmentation therapy […]Read More